Dr. Hans Frickel
Übersicht
4
4
Languages
22
22
years of post-secondary education
9
9
Jahre Berufserfahrung
Berufserfahrung
Managing Director / Member of the Executive Board
R-Biopharm AG
Darmstadt
2018.02 - 2026.01
Key Responsibilities & Achievements
- Headed Quality Management, Occupational Safety, Purchasing & Procurement, IT Infrastructure, Facility Management, Business Process Management and Organisational Development with full financial responsibility for these functions, alongside company-wide accountability as an Executive Board member.
- Aligned quality, regulatory and operational harmonisation through the IVDR transition, supporting international market access. Milestones included ISO 9001 and ISO 13485 recertification and a successful MDSAP audit in 2021, followed by initial IVDR certification in 2022.
- Advisory Board Member, Biotech Park Pfungstadt (08/2019 - 06/2023): Advised on the development of shared biotechnology infrastructure for growing life-science companies.
Strengths Applied
- Maintaining independent judgement where quality, regulatory and commercial priorities meet.
- Developing specialist teams and delegating technical work with clear accountability for decisions.
- Translating strategic decisions into coordinated implementation across specialist functions.
Director IVAC Operations
BioNTech AG
Mainz
2016.08 - 2018.01
Key Responsibilities & Achievements
- Translated personalised mRNA cancer-vaccine research into functioning GCP/GMP operations, linking analytics and manufacturing for clinical development.
- Directed IVAC operations with responsibility for around 70 staff, coordinating R&D, Manufacturing, QC, Quality, IT and Clinical Operations on clinical supply, validation and digital systems.
- Co-led technology transfer with EUFETS and managed the Genentech process and facility set-up collaboration, contributing to the first IVAC clinical trial samples in 2017.
Strengths Applied
- Balancing scientific ambition with regulatory and operational feasibility.
- Sequencing technical work and partner contributions around clinical programme milestones.
- Building shared priorities across scientific, manufacturing, quality and clinical teams.
Executive Advisor & Founder
GrueneNeun GbR
Seeheim
2017.01 - Current
Key Responsibilities & Achievements
- Managing Director, Leon nanodrugs: Integrated development, regulatory affairs, vendor management and budgets into a scalable operating model.
- VP Clinical Manufacturing, Sanner: Established CMC, manufacturing and certification structures for medical devices and combination products under MDR 2017/745.
- Mentor founders through Nucleate on technical scale-up, risk and quality management, regulatory requirements and investment readiness.
Strengths Applied
- Structuring complex scientific and regulatory questions into clear priorities.
- Matching development needs with suitable expertise and partners.
- Aligning responsibilities and decision authority across functions.
Kompetenzen
- Life Sciences Strategy & Development Prioritisation
- Industry Partnerships & Start-up Advisory
- Research Transfer, Platform Technologies & Scale-Up
- Cross-Functional Leadership & Organisational Development
- CMC Strategy & Regulatory Readiness
- Executive Leadership & Financial Accountability
Zeitleiste
Systemisch-integraler Organisationsentwickler -
IHK
2021.06 - 2021.12
Managing Director / Member of the Executive Board
R-Biopharm AG
2018.02 - 2026.01
Executive Advisor & Founder
GrueneNeun GbR
2017.01 - Current
Director IVAC Operations
BioNTech AG
2016.08 - 2018.01
Dr. rer. nat. - Pharmazie
Ruprecht-Karls-Universität
1997.07 - 2002.06
Approbation - Pharmazie
Ruprecht-Karls-Universität
1991.10 - 1997.06
Industriekaufmann -
IHK
1989.08 - 1991.06
Grundwehrdienst -
2. Flugabwehrregiment
1988.07 - 1989.07
Abitur - Allgemeine Hochschulreife
Ludwig-Georgs-Gymnasium
1980.08 - 1988.06
Kurzprofil
Life-sciences executive and advisor helping founders and research teams decide what their technology needs next and build the capabilities and partnerships to make that step possible. My approach brings scientific evidence, regulatory requirements and commercial objectives into the same decision, turning complex questions into clear priorities. Technical depth and executive experience help me judge what a venture can realistically deliver, where specialist partners are needed and how to build development plans that founders can execute and investors can evaluate.
Professional Identity
TECHNICAL JUDGEMENT.
I assess scientific and technical evidence to identify credible development options, their regulatory requirements and the expertise needed to progress.
STRATEGY & ORGANISATION.
Across organisational boundaries, I clarify priorities, partner contributions and decision authority so people can turn a shared strategy into action.
EXECUTIVE RESPONSIBILITY.
In executive roles, I take responsibility for people, budgets and delivery, including the operational, financial and regulatory consequences of decisions.
Qualifications
- Systemic-Integral Organisation Innovator (IHK Wiesbaden)
- Industrial Business Management Assistant (IHK Darmstadt)
- Licensed Pharmacist (Germany)
- Qualified Person (QP), German Medicines Act (AMG)
Education
- Dr. rer. nat., Pharmaceutical Technology, Heidelberg University
- Pharmacy, Heidelberg University
Languages
German: Native speaker
English: C2 - Full professional proficiency
Spanish: A1 - Basic
French: A1 - Basic
Social networks
- Memberships: bioRN; Healthcare Shapers
- Further connections: BRYCK; BioM; BayStartUp
- Dr. Hans Frickel | LinkedIn
https://www.linkedin.com/in/dr-hans-frickel-b893a313/
Target Position
Futury - Cluster Lead Life Sciences
Earlier Positions
- 2013-2016 Director Formulation & Polymer Development and Drug Delivery Global Services Orals, Qualified Person, Evonik Nutrition & Care GmbH, Darmstadt
Oversaw in-house and pharmaceutical client programmes across Germany, India and the USA. - 2005-2013 Director Contract Manufacturing, Platform Technologies & Finished Product Development, Midas Pharma GmbH, Ingelheim
Advanced pharmaceutical platform technologies from formulation to commercial manufacturing through a global CDMO network. - 2003-2005 Head of Pharma Production & Herstellungsleiter (AMG), Procter & Gamble Pharma GmbH, Weiterstadt
Introduced 24/7 commercial manufacturing and guided the operation through a successful FDA inspection. - 2000-2003 Laboratory Head Pharma NCE Development, Merck KGaA, Darmstadt
Supervised NCE analytical development, method transfer and documentation for EU CTX and US IND submissions. - 1997-2000 Research Scientist, ZRW - Retrologistik®, Merck KGaA, Darmstadt
Developed an in-line NIR spectroscopy system from concept to routine industrial use; named co-inventor on the resulting patent.